Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.23
+0.22 (0.92%)
At close: Sep 2, 2025, 4:00 PM
24.21
-0.02 (-0.08%)
After-hours: Sep 2, 2025, 4:40 PM EDT
Castle Biosciences Employees
Castle Biosciences had 761 employees as of December 31, 2024. The number of employees increased by 151 or 24.75% compared to the previous year.
Employees
761
Change (1Y)
151
Growth (1Y)
24.75%
Revenue / Employee
$455,018
Profits / Employee
-$12,439
Market Cap
702.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 761 | 151 | 24.75% |
| Dec 31, 2023 | 610 | 67 | 12.34% |
| Dec 31, 2022 | 543 | 198 | 57.39% |
| Dec 31, 2021 | 345 | 144 | 71.64% |
| Dec 31, 2020 | 201 | 66 | 48.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CSTL News
- 7 hours ago - Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential - Seeking Alpha
- 8 days ago - New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma - GlobeNewsWire
- 12 days ago - Castle Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Castle Biosciences Reports Second Quarter 2025 Results - GlobeNewsWire
- 5 weeks ago - Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 5 weeks ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal - GlobeNewsWire
- 5 weeks ago - FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test - GlobeNewsWire